TNFRSF10B and cancer: After treating the cells with Meso64-TR3/DR5-Fc complexes (necessary to prevent binding directly via TR3, compare Figure 1C), we identified MUC16-negative cells that also lacked the signal for our cancer drug (Figure 5A, DR5-Fc[+], arrows).